News | July 29, 2025
Astec LifeSciences Q1 FY26 revenue up 30.3%
The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year
The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025
RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
Subscribe To Our Newsletter & Stay Updated
